Circulating insulin enters into the brain through mechanisms that are not yet entirely understood. We now report that mice lacking insulin receptors (IR) in astrocytes show reduced uptake of circulating insulin and blunted brain responses to this circulating hormone, suggesting that astrocytes form part of the cellular pathway in the entrance of circulating insulin into the brain. Since we previously showed that ablation of IR in astrocytes decreases brain glucose uptake, we conclude that astrocytic IRs regulate uptake of circulating glucose and insulin.
Introduction
The origin of insulin in the brain has been a matter of debate until relatively recently (Gray et al., 2014) . Early observations documented the presence of insulin in the cerebrospinal fluid (CSF) and the brain (Margolis and Altszuler, 1967; Pansky and Hatfield, 1978) . Because expression of insulin by brain cells was firmly established only recently (Kuwabara, 2011) , for many years, insulin actions in the brain were assumed to arise from pancreatic insulin (Schwartz and Porte, 2005 ) that has to cross the blood-brain-barriers (BBBs). Indeed, there are insulin receptors (IR) in the cells forming the BBBs; that is, epithelial cells at the choroid plexus (Baskin et al., 1986 ), brain capillary endothelial cells (Frank et al., 1986 ) that transcytose insulin (King and Johnson, 1985) , and astrocytes (Baron- Van et al., 1991) . Accordingly, previous observations indicated that insulin from the circulation enters the brain through a transport mechanism involving its receptor in brain endothelial cells forming the BBB (Gray et al., 2017) , although more recent observations indicate that the process may be IR independent (Hersom et al., 2018; Rhea et al., 2018) .
Astrocytes seal brain endothelial cells of brain capillaries by wrapping them with their end-feet (Mathiisen et al., 2010) . In this way, astrocytes constitute an additional cell layer of the BBB (Zlokovic, 2008) . Once insulin has being transported across endothelial cells (King and Johnson, 1985) , it may be taken up by astrocytes either to be further transported into the brain parenchyma through transcytosis (Simionescu et al., 2002) , to modulate the activity of these glial cells (Cai et al., 2018) , or both. To help clarify the route of entrance of circulating insulin into the brain, we analyzed its brain uptake in mice lacking IR in astrocytes. Ablation of IR in astrocytes blocked the entrance of circulating insulin into the brain, suggesting that astrocytes form part of the intracellular pathway of passage of this hormone into the brain.
Results

IR are present in astroglial end-feet
We first determined whether IR are present in astrocytic end-feet ensheathing endothelial cells of the BBB, as its presence in this compartment will allow circulating insulin to readily access astrocytes. Using combined IR immunogold labeling and electron microscopy we localized these receptors in astrocytic end-feet ( Figure 1A,B ).
This anatomical location, in close proximity to endothelial cells, together with the expression of IR in the latter type of cells ( Figure 1B ), or as an yet uncharacterized transporter (Rhea et al., 2018) , would allow the passage of circulating insulin into astrocytes by transcytosis through endothelial cells (Gray et al., 2017) .
Astrocytic IR are required for brain IR activation by circulating insulin
As already documented (Sartorius et al., 2015) , systemic administration of insulin results in robust activation of brain IR (Figure 2A ). However, GFAP IR KO mice show attenuated responses to peripheral insulin injection, as determined by reduced phosphorylation of brain ( Figure 2B ), but not muscle IR ( Figure 2C ). The reduction in brain IR phosphorylation was not due to lower brain IR levels in mutant mice as a result of the ablation of astrocytic IR since receptor activation was normalized by its relative levels (similar between tamoxifen-treated and non-treated mice; see lower blot in Figure   2B ). Furthermore, GFAP IR KO mice show normal brain insulin-like growth factor I (IGF-I) receptor phosphorylation in response to systemic injection of this close relative of insulin (Suppl Fig 1A) , indicating specific loss of sensitivity to systemic insulin.
Astrocytic IR are involved in brain uptake of circulating insulin
To analyze the pathways involved in the passage of circulating insulin into the brain with greater detail, we injected mice with digoxigenin-labelled insulin (Dig-Ins) in the carotid artery and examined its route of entrance by immunolabelling. In control GFAP IR KO mice (not injected with tamoxifen) neuronal digoxigenin staining was readily seen ( Figure 3A , panels b-c, and B). However, in tamoxifen-treated GFAP IR KO mice, neuronal staining was lost ( Figure 3C , panels b-c, and D). In addition, a strong Dig-Ins staining in vessels was seen in these animals ( Figure 3C , panel a, and Suppl Fig 1B) , suggesting that it is retained inside the endothelium without crossing into the brain parenchyma.
Discussion
The first cell layer separating the brain parenchyma from the circulation through the BBB is formed by brain endothelial cells. Whether insulin receptors in these cells are involved in the transport of circulating insulin into the brain, is controversial (King and Johnson, 1985; Gray et al., 2017; Hersom et al., 2018; Rhea et al., 2018) . The second cell layer of the BBB is formed by astrocytic end-feet. The present observations indicate that insulin receptors in astrocytes are involved in the entrance of circulating insulin into the brain. Once insulin is transcytosed by brain endothelial cells through a regulated process, involving or not its receptor (Banks, 2004; Gray et al., 2017) , it is then taken up by astrocytes in a receptor-mediated process to deliver it to neighboring neurons. Hence, circulating insulin access astrocytes not only to modulate their function (Garcia-Caceres et al., 2016; Cai et al., 2018) , but also as a gate of entrance to neurons, as blockade of this pathway results in blockade of neuronal uptake.
Although circulating insulin plays many important roles in the brain, the key question of how it reaches its numerous brain targets remained, until now, poorly characterized. Indeed, it might be of great relevance to know the route of entrance of serum insulin into the brain as in diabetes and several neurodegenerative diseases, brain insulin resistance is a likely pathogenic component. Knowing whether reduced entrance of insulin into the brain and/or loss of sensitivity of brain cells underlie reduced brain insulin function in these pathologies will greatly assist new therapeutic options. In conjunction with recent observations that mice without IR in astrocytes show a depressive phenotype (Cai et al., 2018) , the present results pose astrocytic IRs as important targets for future therapies. Insulin administration: Mice were anesthetized with isofluorane (with oxygen flux at 0.8-1 l/min). The common carotid artery was exposed and the external carotid ligated.
Materials and Methods
Animals
A guide cannula was inserted in the common carotid artery and 100µl Dig-insulin was injected using a Hamilton syringe coupled to a nanoinjector. After 1 hour, mice were perfused with saline and 4% paraformaldehyde. Brains were removed and processed for immunohistochemistry. For IR phosphorylation experiments, mice were injected with 5 IU insulin intraperitoneally. After 1h, mice were perfused with saline and brain and skeletal muscle isolated, frozen until assayed by IR immunoprecipitation and Western blotted with anti-pTyr.
Immunofluorescence: Immunolabeling was performed as described (Fernandez et al., 2012) . Mice were deeply anesthetized with pentobarbital (50 mg/kg), and perfused transcardially with saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 (PB). Brains were dissected, and coronal 50-µm-thick brain sections were cut in a vibratome and collected in PB. Sections were incubated to block non-specific antibody binding, followed by incubation overnight at 4°C with the primary antibodies in PB -1% bovine serum albumin -1% Triton X-100 (PBT). After several washes in PBT, sections were incubated with the corresponding Alexa-coupled secondary antibody (1:1000, Molecular Probes, ThermoFisher Scientific) diluted in PBT. Again, three 5minute washes in PBT were required. Slices were rinsed several times in PB, mounted with gerbatol mounting medium, and allowed to dry. For endothelial cell staining, sections were incubated with Tomato lectin-FITC overnight at 4ºC followed by several washes in PBT. Omission of primary antibodies was used as control. Confocal analysis was performed in a Leica microscope (Wetzlar, Germany).
Immunoprecipitation and Western blotting: Immunoassays were performed as described (Fernandez et al., 2007) . Brain tissue was homogenized in ice-cold buffer with 10mM Tris HCl pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 0.5% NP40, 1mM sodium orthovanadate, and a protease inhibitor cocktail (Sigma) plus 2mM PMSF, using 1 ml of buffer per mg of tissue. Insoluble material was removed by centrifugation, and supernatants were incubated overnight at 4 ºC with the antibodies. Immunocomplexes were collected with Protein A/G agarose (Santa Cruz Biotechnology) for 1 h at 4 °C and washed 3X in homogenization buffer before separation by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. After blocking for 1 h with 5% BSA in TTBS (20 mM Tris-HCl, pH 7.4, 150 M NaCl, 0.1% Tween 20), membranes were incubated overnight at 4 ºC with the different antibodies in TTBS, washed, incubated with secondary antibodies and develop using the Odissey procedure (Li-Cor Biosciences, Lincoln, NE, USA).
Immunoelectron microscopy:
Immunogold procedure was performed as previously described (Gomez-Arboledas et al., 2018) . After deep anesthesia with sodium pentobarbital (60 mg/kg), 6 month-old male mice (C57BL6/J) were perfused transcardially with 0.1 M phosphate-buffered saline (PBS), pH 7.4 followed by fixative solution containing 4% paraformaldehyde, 75 mM lysine and10 mM sodium metaperiodate in 0.1 M PB, pH 7.4. Brains were removed, post-fixed overnight in the same fixative solution at 4°C, coronally sectioned at 50 μm thicknesses on a vibratome (Leica VT1000S), and serially collected in wells containing cold PB and 0.02% sodium azide. For IGF-1R or IR immunogold labelling, sections containing the somatosensory cortex were used. Sections were first washed with PBS and incubated in a 50 mM glycine solution 5 minutes to increase antibody binding efficiency. Following a standard immunohistochemical protocol, tissue was first free-floating incubated in a rabbit polyclonal anti-IGF-IRα antibody or a anti-IR antibody in a PBS 0.1M/1% BSA solution for 48 hours at 22ºC. Then, sections were washed in PBS, and incubated with 1.4 nm gold-conjugated goat anti-rabbit IgG (1:100; Nanoprobes) overnight at 22ºC.
After post-fixing with 2% glutaraldehyde and washing with 50 mM sodium citrate, labelling was enhanced with the HQ Silver TM Kit (Nanoprobes), and gold toned.
Finally, immunogold labelled sections were fixed in 1% osmium tetroxide, block stained with uranyl acetate, dehydrated in acetone, and flat embedded in Araldite 502 (EMS, USA). Selected areas were cut in ultrathin sections (70-80 nm) and examined and photographed with a JEOL JEM1400 electron microscope. As a control for the immunogold technique, sections were processed as above but omitting the primary antibody. No specific labelling was observed in these control sections.
Statistics: Statistical analysis was performed using GraphPad Prism 5.0 (La Jolla, CA, USA). To compare differences between two groups, Student's t-test (Gaussian distribution of data) or Mann-Whitney test (non-Gaussian distribution of data) were used. To compare multiple variables, two-way ANOVA was used, followed by a Bonferroni post hoc test to compare replicate means. Statistical differences were considered when p < 0.05. Results are presented as mean ± SEM of five to eight mice per group. (*p< 0.05, **p< 0.01, ***p< 0.001). Figure 1 : IR is expressed by astrocyte end-feet. A, Electron microscopy photograph using immuno-gold labeling for IR illustrating the presence of immunoeractive IR deposits in astroglial end-feet surrounding brain capillaries and in endothelial cells. B, A1 and A2 squares from A, are shown at greater magnification. Note the presence of IR gold particles in endothelial cells (red arrows) and astrocytic end-feet (black arrows).
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